Ketoprofen
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Ketoprofen
- Ketoprofen: From NSAID Pain and Inflammation Therapy to Acromesomelic Dysplasia, Hunter-Thompson Type
Ketoprofen: From NSAID Pain and Inflammation Therapy to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Ketoprofen is a non-steroidal anti-inflammatory drug (NSAID) that is marketed in the US as oral capsules. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on the model score alone and is likely a knowledge-graph artifact.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the license records; ketoprofen is generally used as an NSAID for pain and inflammation |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.98% (model rank 841) |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 5 (all listed as ANDA generic applications) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known information, ketoprofen is a non-selective COX inhibitor, and its anti-inflammatory and analgesic effects are well established. Mechanistically, however, this does not translate to the predicted new indication.
Acromesomelic dysplasia, Hunter-Thompson type, is a skeletal dysplasia related to CDMP1/GDF5. It is a genetic disorder of bone growth, not an inflammatory disease. No plausible link between COX inhibition and this condition was identified. The very high score (99.98%) is therefore probably a knowledge-graph artifact rather than a real biological signal.
The other top-ranked predictions show the same pattern. Ranks 2 to 7 are also rare skeletal or developmental disorders, such as brachyolmia and pseudoachondroplasia, with no evidence behind them. The only prediction with any supporting logic is spondyloarthropathy, susceptibility to (rank 8). NSAIDs are established first-line symptomatic therapy for spondyloarthritis and reactive arthritis, but that would be class-level symptom control, not novel repurposing. Its single retrieved item (PMID 20470931, a narrative review of reactive arthritis) is only indirect evidence for ketoprofen itself.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The license records do not include approved indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA074014 | Orudis | Capsule | Allegis Pharmaceuticals, Inc. |
| ANDA074014 | Ketoprofen (3 listings) | Capsule | Misemer Pharmaceuticals, Inc. |
| ANDA075679 | Ketoprofen | Capsule, extended release | Mylan Pharmaceuticals Inc. |
All products are oral formulations.
Safety Considerations
Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction data were retrieved for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction has no clinical trials or literature and no plausible mechanistic link. It is a bone-growth genetic disorder, which COX inhibition would not be expected to alter. Nothing supports moving it forward.
To proceed, the following is needed:
- The FDA package insert warnings and contraindications, which are missing and block safety screening
- Mechanism of action data from DrugBank
- If any follow-up is pursued, refocus on spondyloarthropathy (rank 8), where the question is compound-specific efficacy and safety versus other NSAIDs, starting with a targeted literature search and trial registry review
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.